CKD-701 vs Tarcocimab tedromer

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

CKD-701 · Lucenbies

Marketed by Chong Kun Dang Pharmaceutical

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody
Reliable signal

NCT04857177 · Phase 3 · completed

In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.

Reported efficacy

The proportion of patients with a decrease in the best-corrected visual acuity (BCVA) score of 15 or fewer letters at 3 months versus baseline. (Baseline to 3 months): Primary endpoint (proportion with <15-letter BCVA loss at 3 months): 97.95% (CKD-701) vs 98.62% (ranibizumab/Lucentis), P=0.67; between-group difference 0.66% (95% CI −3.63 to 2.32), within the pre-set equivalence margin (±11.5%). (met)

Result source: NCT04857177

Tarcocimab tedromer

Developed by Kodiak Sciences Inc.

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody-biopolymer conjugate
Partial signal

NCT06556368 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)

Result source: NCT04964089

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. CKD-701: 0 of 4 rows · Tarcocimab tedromer: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCKD-701Tarcocimab tedromer
Dropout rate—
8.3%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs—
2.9%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs—
14.1%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs—
covid-19 12.3%
neovascular age-related macular degeneration - fellow eye 8%
vitreous floaters - study eye 7.6%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

CKD-701

BCVA Loss Less Than 15 Letters 97.95% vs 98.62% ranibizumab/Lucentis @ 12.99wk
responder rate · % of participants
NCT04857177 · Phase 3 · sponsor-reported, not registry data

Tarcocimab tedromer

BCVA Change Letters 2.5 vs 4.6 Aflibercept ETDRS Letters @ 44wk
absolute change · ETDRS Letters
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 5 Letters 36.2% (n=276) vs 34.2% (n=281) Aflibercept @ 2wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 2
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 100 Participants as posted
BCVA Gain 5 Letters 39.9% (n=276) vs 45.9% (n=281) Aflibercept @ 4wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 4
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 110 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 53.7% (n=281) Aflibercept @ 8wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 8
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 44.9% (n=276) vs 52.7% (n=281) Aflibercept @ 12wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 12
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 124 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 50.9% (n=281) Aflibercept @ 16wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 16
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 43.8% (n=276) vs 57.3% (n=281) Aflibercept @ 20wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 20
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 121 Participants as posted
BCVA Gain 5 Letters 47.1% (n=276) vs 55.5% (n=281) Aflibercept @ 24wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 24
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 130 Participants as posted
BCVA Gain 5 Letters 44.2% (n=276) vs 54.8% (n=281) Aflibercept @ 28wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 28
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 122 Participants as posted
BCVA Gain 5 Letters 47.8% (n=276) vs 59.8% (n=281) Aflibercept @ 32wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 32
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 132 Participants as posted
BCVA Gain 5 Letters 43.5% (n=276) vs 56.2% (n=281) Aflibercept @ 36wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 36
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 120 Participants as posted
BCVA Gain 5 Letters 42% (n=276) vs 55.5% (n=281) Aflibercept @ 40wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 40
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 116 Participants as posted

+ 68 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-701's landscape · Tarcocimab tedromer's landscape